Comparison of Clinical Effects of Salmeterol/Fluticasone Propionate Combination Products Delivered via Metered-Dose Inhaler with Dry Powder Inhaler in Patients with Moderate Asthma

Comparison of Clinical Effects of Salmeterol/Fluticasone Propionate Combination Products Delivered via Metered-Dose Inhaler with Dry Powder Inhaler in Patients with Moderate Asthma - SFC Diskus vs aerosol inhaler

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009990

Enrollment

Registered

2013-02-08

Start date

2013-02-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bronchial asthma

Interventions

SFC Diskus

wash out

SFC aerosol SFC aerosol

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: The moderate persistent adult asthmatics who had received ICS or ICS/LABA combination inhaler of fluticasone 500 micro-g equivalent daily or less and under well-control status have been recruited.

Exclusion criteria

Exclusion criteria: Current smokers, those who had pulmonary diseases with non reversible airflow obstruction such as COPD or pulmonary fibrosis were excluded.

Design outcomes

Primary

Measure	Time frame
Respiratory resistance and reactance measured by Forced Oscillation Technique (Most Graph)	—

Secondary

Measure	Time frame
FeNO Asthma Control Test score Side effect	—

Countries

Japan

Contacts

Public ContactNahoko Sato

National Center for Global Health and Medicine Devision of Respiratory Medicine

nahoko.t.k.d@gmail.com03-3202-7181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026